0QKQ Stock Overview
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1.29 |
| 52 Week High | CHF6.78 |
| 52 Week Low | CHF1.19 |
| Beta | -14.15 |
| 1 Month Change | -3.01% |
| 3 Month Change | -20.66% |
| 1 Year Change | -80.89% |
| 3 Year Change | -98.20% |
| 5 Year Change | n/a |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QKQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 7.5% | 0.9% | 2.5% |
| 1Y | -80.9% | -22.0% | 5.8% |
Return vs Industry: 0QKQ underperformed the UK Biotechs industry which returned -22.3% over the past year.
Return vs Market: 0QKQ underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0QKQ volatility | |
|---|---|
| 0QKQ Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QKQ's share price has been volatile over the past 3 months.
Volatility Over Time: 0QKQ's weekly volatility has decreased from 13% to 8% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 69 | Michelle Lock | www.relieftherapeutics.com |
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
| 0QKQ fundamental statistics | |
|---|---|
| Market cap | CHF15.68m |
| Earnings (TTM) | -CHF98.18m |
| Revenue (TTM) | CHF6.33m |
2.5x
P/S Ratio-0.2x
P/E RatioIs 0QKQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QKQ income statement (TTM) | |
|---|---|
| Revenue | CHF6.33m |
| Cost of Revenue | CHF1.74m |
| Gross Profit | CHF4.59m |
| Other Expenses | CHF102.77m |
| Earnings | -CHF98.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.83 |
| Gross Margin | 72.57% |
| Net Profit Margin | -1,551.53% |
| Debt/Equity Ratio | 0.7% |
How did 0QKQ perform over the long term?
See historical performance and comparison